Intaglip-M OD 500 Tablet SR is a combination oral antidiabetic medication containing Metformin 500 mg and Vildagliptin 100 mg, formulated as a sustained-release tablet for once-daily administration. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby effectively lowering blood glucose levels in patients with type 2 diabetes mellitus. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases the levels of incretin hormones, which stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner, contributing to improved glycemic control. The combination of these two agents targets multiple pathophysiological defects of type 2 diabetes, offering complementary mechanisms of action to achieve better glycemic control than either agent alone. Intaglip-M OD 500 Tablet SR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, particularly when monotherapy with metformin or vildagliptin is insufficient. The sustained-release formulation enhances patient compliance by reducing dosing frequency and minimizing gastrointestinal side effects commonly associated with metformin. Caution is advised in patients with renal impairment, hepatic dysfunction, or heart failure, and regular monitoring of renal function and glycemic parameters is recommended during therapy.